Apple Pause on Holiday Watch Sales Shows Legal Bind It Faces (1)

Apple Inc.’s plan to halt online sales of its smartwatch four days before Christmas to comply with a regulator’s order shows that it’s in a legal jam.

The company has known for almost two months that a ban imposed by the International Trade Commission would take effect Dec. 25 unless it persuaded the Biden administration to intervene — or worked out a settlement with Masimo Corp., the medical device maker that accused it of copying patented technology for measuring blood-oxygen levels.

The iPhone maker now is racing to make software fixes in a work-around effort to get the product back on the market next year and salvage the $17 billion business generated by its smartwatch sales. The company’s preparations to pull a big moneymaker off the market in the busy holiday season signals that its prospects for relief from the ban are dwindling.

Read More: Apple Plans Rescue for $17 Billion Watch Business in Face of Ban

Intellectual property lawyer James Gagen said it’s striking that in its long-running dispute with Masimo, Apple hadn’t begun the process of obtaining approval for alternative designs earlier or made other arrangements to avoid a halt in sales.

“Normally we would want to have a fallback position so that we could ensure continued supply,” said Gagen, of the firm Allen & Overy LLP.

Patent disputes of the sort that arose between Masimo and Apple in 2020 typically settle before they get to the point where one side is facing a potential sales ban. In this case, Masimo’s allegations of wrongdoing ran deeper than patents: The Irvine, California-based company accused Apple of poaching its employees and stealing trade secrets worth billions of dollars — which the iPhone maker denied. A jury trial this year ended in a stalemate.

Apple could still settle with Masimo, though that’s a route the Cupertino, California-based giant typically prefers not to take.

Masimo Corp. Chief Executive Officer Joe Kiani says Apple should apologize for copying patented technology for measuring blood-oxygen levels. Kiani said he’s willing to work with Apple, but hasn’t heard from anyone. An import ban on certain Apple watches that use the technology is to start Christmas Day. Kiani is on “Bloomberg Technology.”

Source: Bloomberg

Bloomberg Intelligence has estimated that after Masimo gained leverage with its victory at the trade commission and it could negotiate with Apple for a multiyear license in the range of $60 million to $300 million in annual royalties.

Apple has proposed a redesigned smartwatch for review by a branch of the US customs agency, according to November legal filings. But Tamlin Bason, a BI industry analyst, has said that Apple’s requests for the ITC to put its ruling on hold and for an expedited opinion on redesigns for a blood-oxygen sensor were long shots.

Representatives of Apple and Masimo didn’t respond to requests for comment.

Apple has said the ruling from the ITC is erroneous and that it plans to appeal.

The ban “demonstrates that even the world’s most powerful company must abide by the law,” Masimo has said. Its Chief Executive Officer Joe Kiani has said Apple has tested updated Masimo technology that could, if licensed, resolve the patent infringement.

Apple has a few days left to persuade the White House to overrule the ITC ban, but such vetoes are rare. There has been just one in the last decade, when the Obama administration in 2013 halted an iPhone ban stemming from a patent dispute with Samsung Electronics Co.

The fact that the only White House veto issued in a decade was in Apple’s favor might have given the company the impression it could clinch a political victory after a judicial loss, said Nicholas Matich, a former acting general counsel for the US Patent and Trademark Office.

“Apple may be feeling a little bit of invincibility,” said Matich, who is now at law firm McKool Smith PC.

Still, Matich doesn’t think Apple is at a dead end. A software workaround seems like a viable strategy to rescue its product without making concessions to Masimo, he said.

“The patent suit pertains to one very specific feature of Apple’s product,” he said. “Apple can remove the feature and then it’s not infringing.”

(Updates with Bloomberg Intelligence analyst in ninth paragraph.)

--With assistance from Christopher Yasiejko and Mark Gurman.

To contact the reporter on this story:
Rachel Graf in San Francisco at rgraf27@bloomberg.net

To contact the editors responsible for this story:
Peter Blumberg at pblumberg1@bloomberg.net

Molly Schuetz, Misyrlena Egkolfopoulou

© 2023 Bloomberg L.P. All rights reserved. Used with permission.